Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).

Authors

• William Kelly

Publication/Presentation Date

5-2020

Volume

38

Issue

15

Published In/Presented At

DOI: 10.1200/JCO.2020.38.15_suppl.5540

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article